MetaCap

Compass Therapeutics Cash Flow Statement

NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6882+0.0097 (+1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Compass Therapeutics free cash flow

In fiscal 2025, Compass Therapeutics generated -$49.1 million of operating cash flow and spent $25,000 on capital expenditures. That left free cash flow of -$49.2 million.

Summary generated from market data by MetaCap's automated system. Methodology

Compass Therapeutics cash flow statement (annual)

Compass Therapeutics annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20202020-03-31FY 20192019-12-31FY 20192019-03-31
Net Income-66.49M-49.38M-42.49M-39.23M-82.18M-29.50M-37.48K-34.74M-36.04K
Net Income growth (YoY)—————————
Depreciation & Amortization276.00K589.00K699.00K782.00K600.00K2.40M—2.10M—
Stock-Based Compensation8.37M8.56M6.12M5.33M4.03M4.02M—915.00K—
Change in Working Capital9.55M-2.92M-1.71M-161.00K7.36M-3.31M5.38K-157.00K3.28K
Operating Cash Flow-49.14M-44.85M-40.62M-34.13M-19.67M-26.80M-32.11K-31.74M-32.76K
Capital Expenditures-25.00K-44.00K-30.00K-212.00K-1.57M-106.00K—-466.00K—
Investing Cash Flow-93.31M46.77M26.96M-151.20M-1.77M38.00K—-466.00K—
Debt Repaid———0-9.38M-5.63M———
Financing Cash Flow129.61M17.34M2.94M75.76M118.61M48.54M30.98K—37.63K
Net Change in Cash-12.84M19.25M-10.72M-109.57M97.17M21.77M-1.12K-32.21M4.87K
Free Cash Flow-49.17M-44.90M-40.65M-34.34M-21.23M-26.91M-32.11K-32.21M-32.76K

This table shows 9 annual periods of Compass Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a cash flow statement?

More financial data